Melanoma models for the next generation of therapies

E. Elizabeth Patton; Kristen L. Mueller; David J. Adams; Niroshana Anandasabapathy; Andrew E. Aplin; Corine Bertolotto; Marcus Bosenberg; Craig J. Ceol; Christin E. Burd; Ping Chi; Meenhard Herlyn; Sheri L. Holmen; Florian A. Karreth; Charles K. Kaufman; Shaheen Khan; Sebastian Kobold; Eleonora Leucci; Carmit Levy; David B. Lombard; Amanda W. Lund; Kerrie L. Marie; Jean Christophe Marine; Richard Marais; Martin McMahon; Carla Daniela Robles-Espinoza; Ze'ev A. Ronai; Yardena Samuels; Maria S. Soengas; Jessie Villanueva; Ashani T. Weeraratna; Richard M. White; Iwei Yeh; Jiyue Zhu; Leonard I. Zon; Marc S. Hurlbert; Glenn Merlino

doi:10.1016/j.ccell.2021.01.011

Melanoma models for the next generation of therapies

E. Elizabeth Patton, Kristen L. Mueller, David J. Adams, Niroshana Anandasabapathy, Andrew E. Aplin, Corine Bertolotto, Marcus Bosenberg, Craig J. Ceol, Christin E. Burd, Ping Chi, Meenhard Herlyn, Sheri L. Holmen, Florian A. Karreth, Charles K. Kaufman, Shaheen Khan, Sebastian Kobold, Eleonora Leucci, Carmit Levy, David B. Lombard, Amanda W. LundKerrie L. Marie, Jean Christophe Marine, Richard Marais, Martin McMahon, Carla Daniela Robles-Espinoza, Ze'ev A. Ronai, Yardena Samuels, Maria S. Soengas, Jessie Villanueva, Ashani T. Weeraratna, Richard M. White, Iwei Yeh, Jiyue Zhu, Leonard I. Zon, Marc S. Hurlbert, Glenn Merlino

Tel Aviv University, Weizmann Institute of Science

Research output: Contribution to journal › Review article › peer-review

Abstract

There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies.

Original language	English
Pages (from-to)	610-631
Number of pages	22
Journal	Cancer Cell
Volume	39
Issue number	5
DOIs	https://doi.org/10.1016/j.ccell.2021.01.011
State	Published - 10 May 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Animals
Disease Models, Animal
Humans
Immunity/immunology
Immunotherapy/methods
Melanoma/drug therapy
Skin Neoplasms/drug therapy
Tumor Microenvironment/immunology
animal models
drug discovery
immunotherapy
melanoma
targeted therapy
therapeutics
tumor microenvironment

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research
Cell Biology

Access to Document

10.1016/j.ccell.2021.01.011

ys_CancerCell_MelanomaModels_AM2021.pdfAccepted author manuscript, 2.53 MBLicense: Other

Cite this

Patton, E. E., Mueller, K. L., Adams, D. J., Anandasabapathy, N., Aplin, A. E., Bertolotto, C., Bosenberg, M., Ceol, C. J., Burd, C. E., Chi, P., Herlyn, M., Holmen, S. L., Karreth, F. A., Kaufman, C. K., Khan, S., Kobold, S., Leucci, E., Levy, C., Lombard, D. B., ... Merlino, G. (2021). Melanoma models for the next generation of therapies. Cancer Cell, 39(5), 610-631. https://doi.org/10.1016/j.ccell.2021.01.011

@article{1d4bee91961c43aa848c82606bd5a21e,

title = "Melanoma models for the next generation of therapies",

abstract = "There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies.",

keywords = "Animals, Disease Models, Animal, Humans, Immunity/immunology, Immunotherapy/methods, Melanoma/drug therapy, Skin Neoplasms/drug therapy, Tumor Microenvironment/immunology, animal models, drug discovery, immunotherapy, melanoma, targeted therapy, therapeutics, tumor microenvironment",

author = "Patton, \{E. Elizabeth\} and Mueller, \{Kristen L.\} and Adams, \{David J.\} and Niroshana Anandasabapathy and Aplin, \{Andrew E.\} and Corine Bertolotto and Marcus Bosenberg and Ceol, \{Craig J.\} and Burd, \{Christin E.\} and Ping Chi and Meenhard Herlyn and Holmen, \{Sheri L.\} and Karreth, \{Florian A.\} and Kaufman, \{Charles K.\} and Shaheen Khan and Sebastian Kobold and Eleonora Leucci and Carmit Levy and Lombard, \{David B.\} and Lund, \{Amanda W.\} and Marie, \{Kerrie L.\} and Marine, \{Jean Christophe\} and Richard Marais and Martin McMahon and Robles-Espinoza, \{Carla Daniela\} and Ronai, \{Ze'ev A.\} and Yardena Samuels and Soengas, \{Maria S.\} and Jessie Villanueva and Weeraratna, \{Ashani T.\} and White, \{Richard M.\} and Iwei Yeh and Jiyue Zhu and Zon, \{Leonard I.\} and Hurlbert, \{Marc S.\} and Glenn Merlino",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = may,

day = "10",

doi = "10.1016/j.ccell.2021.01.011",

language = "الإنجليزيّة",

volume = "39",

pages = "610--631",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "5",

}

Patton, EE, Mueller, KL, Adams, DJ, Anandasabapathy, N, Aplin, AE, Bertolotto, C, Bosenberg, M, Ceol, CJ, Burd, CE, Chi, P, Herlyn, M, Holmen, SL, Karreth, FA, Kaufman, CK, Khan, S, Kobold, S, Leucci, E, Levy, C, Lombard, DB, Lund, AW, Marie, KL, Marine, JC, Marais, R, McMahon, M, Robles-Espinoza, CD, Ronai, ZA, Samuels, Y, Soengas, MS, Villanueva, J, Weeraratna, AT, White, RM, Yeh, I, Zhu, J, Zon, LI, Hurlbert, MS & Merlino, G 2021, 'Melanoma models for the next generation of therapies', Cancer Cell, vol. 39, no. 5, pp. 610-631. https://doi.org/10.1016/j.ccell.2021.01.011

TY - JOUR

T1 - Melanoma models for the next generation of therapies

AU - Patton, E. Elizabeth

AU - Mueller, Kristen L.

AU - Adams, David J.

AU - Anandasabapathy, Niroshana

AU - Aplin, Andrew E.

AU - Bertolotto, Corine

AU - Bosenberg, Marcus

AU - Ceol, Craig J.

AU - Burd, Christin E.

AU - Chi, Ping

AU - Herlyn, Meenhard

AU - Holmen, Sheri L.

AU - Karreth, Florian A.

AU - Kaufman, Charles K.

AU - Khan, Shaheen

AU - Kobold, Sebastian

AU - Leucci, Eleonora

AU - Levy, Carmit

AU - Lombard, David B.

AU - Lund, Amanda W.

AU - Marie, Kerrie L.

AU - Marine, Jean Christophe

AU - Marais, Richard

AU - McMahon, Martin

AU - Robles-Espinoza, Carla Daniela

AU - Ronai, Ze'ev A.

AU - Samuels, Yardena

AU - Soengas, Maria S.

AU - Villanueva, Jessie

AU - Weeraratna, Ashani T.

AU - White, Richard M.

AU - Yeh, Iwei

AU - Zhu, Jiyue

AU - Zon, Leonard I.

AU - Hurlbert, Marc S.

AU - Merlino, Glenn

PY - 2021/5/10

Y1 - 2021/5/10

N2 - There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies.

AB - There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies.

KW - Animals

KW - Disease Models, Animal

KW - Humans

KW - Immunity/immunology

KW - Immunotherapy/methods

KW - Melanoma/drug therapy

KW - Skin Neoplasms/drug therapy

KW - Tumor Microenvironment/immunology

KW - animal models

KW - drug discovery

KW - immunotherapy

KW - melanoma

KW - targeted therapy

KW - therapeutics

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85100410854&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2021.01.011

DO - 10.1016/j.ccell.2021.01.011

M3 - مقالة مرجعية

C2 - 33545064

SN - 1535-6108

VL - 39

SP - 610

EP - 631

JO - Cancer Cell

JF - Cancer Cell

IS - 5

ER -

Melanoma models for the next generation of therapies

Abstract

UN SDGs

Keywords

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this